Global Live and Attenuated Vaccine Market Growth 2026-2032
The global Live and Attenuated Vaccine market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for Live and Attenuated Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Live and Attenuated Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Live and Attenuated Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Live and Attenuated Vaccine players cover GlaxoSmithKline, Merck & Co., Pfizer, Inc, Astellas Pharma Inc, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Live and Attenuated Vaccine Industry Forecast? looks at past sales and reviews total world Live and Attenuated Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Live and Attenuated Vaccine sales for 2026 through 2032. With Live and Attenuated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Live and Attenuated Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Live and Attenuated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Live and Attenuated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Live and Attenuated Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Live and Attenuated Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Live and Attenuated Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Live and Attenuated Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
United States market for Live and Attenuated Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Live and Attenuated Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Live and Attenuated Vaccine is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Live and Attenuated Vaccine players cover GlaxoSmithKline, Merck & Co., Pfizer, Inc, Astellas Pharma Inc, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Live and Attenuated Vaccine Industry Forecast? looks at past sales and reviews total world Live and Attenuated Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Live and Attenuated Vaccine sales for 2026 through 2032. With Live and Attenuated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Live and Attenuated Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Live and Attenuated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Live and Attenuated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Live and Attenuated Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Live and Attenuated Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Live and Attenuated Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Live and Attenuated Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Pediatric Vaccine
- Adult Vaccines
- Hospitals
- Clinics
- Diagnostic Centers
- Research Institute
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GlaxoSmithKline
- Merck & Co.
- Pfizer, Inc
- Astellas Pharma Inc
- Johnson & Johnson
- CSL Limited
- Emergent BioSolutions, Inc.
- MedImmune, LLC
- Sanofi
- Serum Institute
- What is the 10-year outlook for the global Live and Attenuated Vaccine market?
- What factors are driving Live and Attenuated Vaccine market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Live and Attenuated Vaccine market opportunities vary by end market size?
- How does Live and Attenuated Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Live and Attenuated Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Live and Attenuated Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Live and Attenuated Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Live and Attenuated Vaccine Segment by Type
2.2.1 Pediatric Vaccine
2.2.2 Adult Vaccines
2.2.3 Live and Attenuated Vaccine Sales by Type
2.2.3.1 Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global Live and Attenuated Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Live and Attenuated Vaccine Sale Price by Type (2021-2026)
2.3 Live and Attenuated Vaccine Segment by Application
2.3.1 Hospitals
2.3.2 Clinics
2.3.3 Diagnostic Centers
2.3.4 Research Institute
2.3.5 Others
2.3.6 Live and Attenuated Vaccine Sales by Application
2.3.6.1 Global Live and Attenuated Vaccine Sale Market Share by Application (2021-2026)
2.3.6.2 Global Live and Attenuated Vaccine Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Live and Attenuated Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Live and Attenuated Vaccine Breakdown Data by Company
3.1.1 Global Live and Attenuated Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Live and Attenuated Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Live and Attenuated Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Live and Attenuated Vaccine Revenue by Company (2021-2026)
3.2.2 Global Live and Attenuated Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Live and Attenuated Vaccine Sale Price by Company
3.4 Key Manufacturers Live and Attenuated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Live and Attenuated Vaccine Product Location Distribution
3.4.2 Players Live and Attenuated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LIVE AND ATTENUATED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Live and Attenuated Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Live and Attenuated Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Live and Attenuated Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Live and Attenuated Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Live and Attenuated Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Live and Attenuated Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Live and Attenuated Vaccine Sales Growth
4.4 APAC Live and Attenuated Vaccine Sales Growth
4.5 Europe Live and Attenuated Vaccine Sales Growth
4.6 Middle East & Africa Live and Attenuated Vaccine Sales Growth
5 AMERICAS
5.1 Americas Live and Attenuated Vaccine Sales by Country
5.1.1 Americas Live and Attenuated Vaccine Sales by Country (2021-2026)
5.1.2 Americas Live and Attenuated Vaccine Revenue by Country (2021-2026)
5.2 Americas Live and Attenuated Vaccine Sales by Type (2021-2026)
5.3 Americas Live and Attenuated Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Live and Attenuated Vaccine Sales by Region
6.1.1 APAC Live and Attenuated Vaccine Sales by Region (2021-2026)
6.1.2 APAC Live and Attenuated Vaccine Revenue by Region (2021-2026)
6.2 APAC Live and Attenuated Vaccine Sales by Type (2021-2026)
6.3 APAC Live and Attenuated Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Live and Attenuated Vaccine by Country
7.1.1 Europe Live and Attenuated Vaccine Sales by Country (2021-2026)
7.1.2 Europe Live and Attenuated Vaccine Revenue by Country (2021-2026)
7.2 Europe Live and Attenuated Vaccine Sales by Type (2021-2026)
7.3 Europe Live and Attenuated Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Live and Attenuated Vaccine by Country
8.1.1 Middle East & Africa Live and Attenuated Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Live and Attenuated Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Live and Attenuated Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Live and Attenuated Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Live and Attenuated Vaccine
10.3 Manufacturing Process Analysis of Live and Attenuated Vaccine
10.4 Industry Chain Structure of Live and Attenuated Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Live and Attenuated Vaccine Distributors
11.3 Live and Attenuated Vaccine Customer
12 WORLD FORECAST REVIEW FOR LIVE AND ATTENUATED VACCINE BY GEOGRAPHIC REGION
12.1 Global Live and Attenuated Vaccine Market Size Forecast by Region
12.1.1 Global Live and Attenuated Vaccine Forecast by Region (2027-2032)
12.1.2 Global Live and Attenuated Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Live and Attenuated Vaccine Forecast by Type (2027-2032)
12.7 Global Live and Attenuated Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolios and Specifications
13.1.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Merck & Co.
13.2.1 Merck & Co. Company Information
13.2.2 Merck & Co. Live and Attenuated Vaccine Product Portfolios and Specifications
13.2.3 Merck & Co. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck & Co. Main Business Overview
13.2.5 Merck & Co. Latest Developments
13.3 Pfizer, Inc
13.3.1 Pfizer, Inc Company Information
13.3.2 Pfizer, Inc Live and Attenuated Vaccine Product Portfolios and Specifications
13.3.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer, Inc Main Business Overview
13.3.5 Pfizer, Inc Latest Developments
13.4 Astellas Pharma Inc
13.4.1 Astellas Pharma Inc Company Information
13.4.2 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolios and Specifications
13.4.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Astellas Pharma Inc Main Business Overview
13.4.5 Astellas Pharma Inc Latest Developments
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Information
13.5.2 Johnson & Johnson Live and Attenuated Vaccine Product Portfolios and Specifications
13.5.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Johnson & Johnson Main Business Overview
13.5.5 Johnson & Johnson Latest Developments
13.6 CSL Limited
13.6.1 CSL Limited Company Information
13.6.2 CSL Limited Live and Attenuated Vaccine Product Portfolios and Specifications
13.6.3 CSL Limited Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CSL Limited Main Business Overview
13.6.5 CSL Limited Latest Developments
13.7 Emergent BioSolutions, Inc.
13.7.1 Emergent BioSolutions, Inc. Company Information
13.7.2 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolios and Specifications
13.7.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Emergent BioSolutions, Inc. Main Business Overview
13.7.5 Emergent BioSolutions, Inc. Latest Developments
13.8 MedImmune, LLC
13.8.1 MedImmune, LLC Company Information
13.8.2 MedImmune, LLC Live and Attenuated Vaccine Product Portfolios and Specifications
13.8.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 MedImmune, LLC Main Business Overview
13.8.5 MedImmune, LLC Latest Developments
13.9 Sanofi
13.9.1 Sanofi Company Information
13.9.2 Sanofi Live and Attenuated Vaccine Product Portfolios and Specifications
13.9.3 Sanofi Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Sanofi Main Business Overview
13.9.5 Sanofi Latest Developments
13.10 Serum Institute
13.10.1 Serum Institute Company Information
13.10.2 Serum Institute Live and Attenuated Vaccine Product Portfolios and Specifications
13.10.3 Serum Institute Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Serum Institute Main Business Overview
13.10.5 Serum Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Live and Attenuated Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Live and Attenuated Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Live and Attenuated Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Live and Attenuated Vaccine Segment by Type
2.2.1 Pediatric Vaccine
2.2.2 Adult Vaccines
2.2.3 Live and Attenuated Vaccine Sales by Type
2.2.3.1 Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global Live and Attenuated Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Live and Attenuated Vaccine Sale Price by Type (2021-2026)
2.3 Live and Attenuated Vaccine Segment by Application
2.3.1 Hospitals
2.3.2 Clinics
2.3.3 Diagnostic Centers
2.3.4 Research Institute
2.3.5 Others
2.3.6 Live and Attenuated Vaccine Sales by Application
2.3.6.1 Global Live and Attenuated Vaccine Sale Market Share by Application (2021-2026)
2.3.6.2 Global Live and Attenuated Vaccine Revenue and Market Share by Application (2021-2026)
2.3.6.3 Global Live and Attenuated Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Live and Attenuated Vaccine Breakdown Data by Company
3.1.1 Global Live and Attenuated Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Live and Attenuated Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Live and Attenuated Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Live and Attenuated Vaccine Revenue by Company (2021-2026)
3.2.2 Global Live and Attenuated Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Live and Attenuated Vaccine Sale Price by Company
3.4 Key Manufacturers Live and Attenuated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Live and Attenuated Vaccine Product Location Distribution
3.4.2 Players Live and Attenuated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR LIVE AND ATTENUATED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Live and Attenuated Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Live and Attenuated Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Live and Attenuated Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Live and Attenuated Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Live and Attenuated Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Live and Attenuated Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Live and Attenuated Vaccine Sales Growth
4.4 APAC Live and Attenuated Vaccine Sales Growth
4.5 Europe Live and Attenuated Vaccine Sales Growth
4.6 Middle East & Africa Live and Attenuated Vaccine Sales Growth
5 AMERICAS
5.1 Americas Live and Attenuated Vaccine Sales by Country
5.1.1 Americas Live and Attenuated Vaccine Sales by Country (2021-2026)
5.1.2 Americas Live and Attenuated Vaccine Revenue by Country (2021-2026)
5.2 Americas Live and Attenuated Vaccine Sales by Type (2021-2026)
5.3 Americas Live and Attenuated Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Live and Attenuated Vaccine Sales by Region
6.1.1 APAC Live and Attenuated Vaccine Sales by Region (2021-2026)
6.1.2 APAC Live and Attenuated Vaccine Revenue by Region (2021-2026)
6.2 APAC Live and Attenuated Vaccine Sales by Type (2021-2026)
6.3 APAC Live and Attenuated Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Live and Attenuated Vaccine by Country
7.1.1 Europe Live and Attenuated Vaccine Sales by Country (2021-2026)
7.1.2 Europe Live and Attenuated Vaccine Revenue by Country (2021-2026)
7.2 Europe Live and Attenuated Vaccine Sales by Type (2021-2026)
7.3 Europe Live and Attenuated Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Live and Attenuated Vaccine by Country
8.1.1 Middle East & Africa Live and Attenuated Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Live and Attenuated Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Live and Attenuated Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Live and Attenuated Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Live and Attenuated Vaccine
10.3 Manufacturing Process Analysis of Live and Attenuated Vaccine
10.4 Industry Chain Structure of Live and Attenuated Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Live and Attenuated Vaccine Distributors
11.3 Live and Attenuated Vaccine Customer
12 WORLD FORECAST REVIEW FOR LIVE AND ATTENUATED VACCINE BY GEOGRAPHIC REGION
12.1 Global Live and Attenuated Vaccine Market Size Forecast by Region
12.1.1 Global Live and Attenuated Vaccine Forecast by Region (2027-2032)
12.1.2 Global Live and Attenuated Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Live and Attenuated Vaccine Forecast by Type (2027-2032)
12.7 Global Live and Attenuated Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolios and Specifications
13.1.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Merck & Co.
13.2.1 Merck & Co. Company Information
13.2.2 Merck & Co. Live and Attenuated Vaccine Product Portfolios and Specifications
13.2.3 Merck & Co. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck & Co. Main Business Overview
13.2.5 Merck & Co. Latest Developments
13.3 Pfizer, Inc
13.3.1 Pfizer, Inc Company Information
13.3.2 Pfizer, Inc Live and Attenuated Vaccine Product Portfolios and Specifications
13.3.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer, Inc Main Business Overview
13.3.5 Pfizer, Inc Latest Developments
13.4 Astellas Pharma Inc
13.4.1 Astellas Pharma Inc Company Information
13.4.2 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolios and Specifications
13.4.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Astellas Pharma Inc Main Business Overview
13.4.5 Astellas Pharma Inc Latest Developments
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Information
13.5.2 Johnson & Johnson Live and Attenuated Vaccine Product Portfolios and Specifications
13.5.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Johnson & Johnson Main Business Overview
13.5.5 Johnson & Johnson Latest Developments
13.6 CSL Limited
13.6.1 CSL Limited Company Information
13.6.2 CSL Limited Live and Attenuated Vaccine Product Portfolios and Specifications
13.6.3 CSL Limited Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CSL Limited Main Business Overview
13.6.5 CSL Limited Latest Developments
13.7 Emergent BioSolutions, Inc.
13.7.1 Emergent BioSolutions, Inc. Company Information
13.7.2 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolios and Specifications
13.7.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Emergent BioSolutions, Inc. Main Business Overview
13.7.5 Emergent BioSolutions, Inc. Latest Developments
13.8 MedImmune, LLC
13.8.1 MedImmune, LLC Company Information
13.8.2 MedImmune, LLC Live and Attenuated Vaccine Product Portfolios and Specifications
13.8.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 MedImmune, LLC Main Business Overview
13.8.5 MedImmune, LLC Latest Developments
13.9 Sanofi
13.9.1 Sanofi Company Information
13.9.2 Sanofi Live and Attenuated Vaccine Product Portfolios and Specifications
13.9.3 Sanofi Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Sanofi Main Business Overview
13.9.5 Sanofi Latest Developments
13.10 Serum Institute
13.10.1 Serum Institute Company Information
13.10.2 Serum Institute Live and Attenuated Vaccine Product Portfolios and Specifications
13.10.3 Serum Institute Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Serum Institute Main Business Overview
13.10.5 Serum Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Live and Attenuated Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Live and Attenuated Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Pediatric Vaccine
Table 4. Major Players of Adult Vaccines
Table 5. Global Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 6. Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Live and Attenuated Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Live and Attenuated Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Live and Attenuated Vaccine Sale by Application (2021-2026) & (K Units)
Table 11. Global Live and Attenuated Vaccine Sale Market Share by Application (2021-2026)
Table 12. Global Live and Attenuated Vaccine Revenue by Application (2021-2026) & ($ million)
Table 13. Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2026)
Table 14. Global Live and Attenuated Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Live and Attenuated Vaccine Sales by Company (2021-2026) & (K Units)
Table 16. Global Live and Attenuated Vaccine Sales Market Share by Company (2021-2026)
Table 17. Global Live and Attenuated Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Live and Attenuated Vaccine Revenue Market Share by Company (2021-2026)
Table 19. Global Live and Attenuated Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Live and Attenuated Vaccine Producing Area Distribution and Sales Area
Table 21. Players Live and Attenuated Vaccine Products Offered
Table 22. Live and Attenuated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Live and Attenuated Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Live and Attenuated Vaccine Sales Market Share Geographic Region (2021-2026)
Table 27. Global Live and Attenuated Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Live and Attenuated Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Live and Attenuated Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Live and Attenuated Vaccine Sales Market Share by Country/Region (2021-2026)
Table 31. Global Live and Attenuated Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Live and Attenuated Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Live and Attenuated Vaccine Sales by Country (2021-2026) & (K Units)
Table 34. Americas Live and Attenuated Vaccine Sales Market Share by Country (2021-2026)
Table 35. Americas Live and Attenuated Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 37. Americas Live and Attenuated Vaccine Sales by Application (2021-2026) & (K Units)
Table 38. APAC Live and Attenuated Vaccine Sales by Region (2021-2026) & (K Units)
Table 39. APAC Live and Attenuated Vaccine Sales Market Share by Region (2021-2026)
Table 40. APAC Live and Attenuated Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 42. APAC Live and Attenuated Vaccine Sales by Application (2021-2026) & (K Units)
Table 43. Europe Live and Attenuated Vaccine Sales by Country (2021-2026) & (K Units)
Table 44. Europe Live and Attenuated Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Europe Live and Attenuated Vaccine Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Live and Attenuated Vaccine Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Live and Attenuated Vaccine Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Live and Attenuated Vaccine Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Live and Attenuated Vaccine
Table 52. Key Market Challenges & Risks of Live and Attenuated Vaccine
Table 53. Key Industry Trends of Live and Attenuated Vaccine
Table 54. Live and Attenuated Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Live and Attenuated Vaccine Distributors List
Table 57. Live and Attenuated Vaccine Customer List
Table 58. Global Live and Attenuated Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Live and Attenuated Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Live and Attenuated Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Live and Attenuated Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Live and Attenuated Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Live and Attenuated Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Live and Attenuated Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Live and Attenuated Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Live and Attenuated Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Live and Attenuated Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Live and Attenuated Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. GlaxoSmithKline Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. GlaxoSmithKline Live and Attenuated Vaccine Product Portfolios and Specifications
Table 74. GlaxoSmithKline Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. GlaxoSmithKline Main Business
Table 76. GlaxoSmithKline Latest Developments
Table 77. Merck & Co. Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Merck & Co. Live and Attenuated Vaccine Product Portfolios and Specifications
Table 79. Merck & Co. Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Merck & Co. Main Business
Table 81. Merck & Co. Latest Developments
Table 82. Pfizer, Inc Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer, Inc Live and Attenuated Vaccine Product Portfolios and Specifications
Table 84. Pfizer, Inc Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Pfizer, Inc Main Business
Table 86. Pfizer, Inc Latest Developments
Table 87. Astellas Pharma Inc Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolios and Specifications
Table 89. Astellas Pharma Inc Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Astellas Pharma Inc Main Business
Table 91. Astellas Pharma Inc Latest Developments
Table 92. Johnson & Johnson Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Johnson & Johnson Live and Attenuated Vaccine Product Portfolios and Specifications
Table 94. Johnson & Johnson Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Johnson & Johnson Main Business
Table 96. Johnson & Johnson Latest Developments
Table 97. CSL Limited Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. CSL Limited Live and Attenuated Vaccine Product Portfolios and Specifications
Table 99. CSL Limited Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. CSL Limited Main Business
Table 101. CSL Limited Latest Developments
Table 102. Emergent BioSolutions, Inc. Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolios and Specifications
Table 104. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Emergent BioSolutions, Inc. Main Business
Table 106. Emergent BioSolutions, Inc. Latest Developments
Table 107. MedImmune, LLC Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. MedImmune, LLC Live and Attenuated Vaccine Product Portfolios and Specifications
Table 109. MedImmune, LLC Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. MedImmune, LLC Main Business
Table 111. MedImmune, LLC Latest Developments
Table 112. Sanofi Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Sanofi Live and Attenuated Vaccine Product Portfolios and Specifications
Table 114. Sanofi Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Sanofi Main Business
Table 116. Sanofi Latest Developments
Table 117. Serum Institute Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Serum Institute Live and Attenuated Vaccine Product Portfolios and Specifications
Table 119. Serum Institute Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Serum Institute Main Business
Table 121. Serum Institute Latest Developments
Table 1. Live and Attenuated Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Live and Attenuated Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Pediatric Vaccine
Table 4. Major Players of Adult Vaccines
Table 5. Global Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 6. Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Live and Attenuated Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Live and Attenuated Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Live and Attenuated Vaccine Sale by Application (2021-2026) & (K Units)
Table 11. Global Live and Attenuated Vaccine Sale Market Share by Application (2021-2026)
Table 12. Global Live and Attenuated Vaccine Revenue by Application (2021-2026) & ($ million)
Table 13. Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2026)
Table 14. Global Live and Attenuated Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Live and Attenuated Vaccine Sales by Company (2021-2026) & (K Units)
Table 16. Global Live and Attenuated Vaccine Sales Market Share by Company (2021-2026)
Table 17. Global Live and Attenuated Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Live and Attenuated Vaccine Revenue Market Share by Company (2021-2026)
Table 19. Global Live and Attenuated Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Live and Attenuated Vaccine Producing Area Distribution and Sales Area
Table 21. Players Live and Attenuated Vaccine Products Offered
Table 22. Live and Attenuated Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Live and Attenuated Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Live and Attenuated Vaccine Sales Market Share Geographic Region (2021-2026)
Table 27. Global Live and Attenuated Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Live and Attenuated Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Live and Attenuated Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Live and Attenuated Vaccine Sales Market Share by Country/Region (2021-2026)
Table 31. Global Live and Attenuated Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Live and Attenuated Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Live and Attenuated Vaccine Sales by Country (2021-2026) & (K Units)
Table 34. Americas Live and Attenuated Vaccine Sales Market Share by Country (2021-2026)
Table 35. Americas Live and Attenuated Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 37. Americas Live and Attenuated Vaccine Sales by Application (2021-2026) & (K Units)
Table 38. APAC Live and Attenuated Vaccine Sales by Region (2021-2026) & (K Units)
Table 39. APAC Live and Attenuated Vaccine Sales Market Share by Region (2021-2026)
Table 40. APAC Live and Attenuated Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 42. APAC Live and Attenuated Vaccine Sales by Application (2021-2026) & (K Units)
Table 43. Europe Live and Attenuated Vaccine Sales by Country (2021-2026) & (K Units)
Table 44. Europe Live and Attenuated Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Europe Live and Attenuated Vaccine Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Live and Attenuated Vaccine Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Live and Attenuated Vaccine Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Live and Attenuated Vaccine Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Live and Attenuated Vaccine Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Live and Attenuated Vaccine
Table 52. Key Market Challenges & Risks of Live and Attenuated Vaccine
Table 53. Key Industry Trends of Live and Attenuated Vaccine
Table 54. Live and Attenuated Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Live and Attenuated Vaccine Distributors List
Table 57. Live and Attenuated Vaccine Customer List
Table 58. Global Live and Attenuated Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Live and Attenuated Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Live and Attenuated Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Live and Attenuated Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Live and Attenuated Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Live and Attenuated Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Live and Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Live and Attenuated Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Live and Attenuated Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Live and Attenuated Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Live and Attenuated Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Live and Attenuated Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. GlaxoSmithKline Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. GlaxoSmithKline Live and Attenuated Vaccine Product Portfolios and Specifications
Table 74. GlaxoSmithKline Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. GlaxoSmithKline Main Business
Table 76. GlaxoSmithKline Latest Developments
Table 77. Merck & Co. Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Merck & Co. Live and Attenuated Vaccine Product Portfolios and Specifications
Table 79. Merck & Co. Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Merck & Co. Main Business
Table 81. Merck & Co. Latest Developments
Table 82. Pfizer, Inc Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer, Inc Live and Attenuated Vaccine Product Portfolios and Specifications
Table 84. Pfizer, Inc Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Pfizer, Inc Main Business
Table 86. Pfizer, Inc Latest Developments
Table 87. Astellas Pharma Inc Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolios and Specifications
Table 89. Astellas Pharma Inc Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Astellas Pharma Inc Main Business
Table 91. Astellas Pharma Inc Latest Developments
Table 92. Johnson & Johnson Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. Johnson & Johnson Live and Attenuated Vaccine Product Portfolios and Specifications
Table 94. Johnson & Johnson Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Johnson & Johnson Main Business
Table 96. Johnson & Johnson Latest Developments
Table 97. CSL Limited Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. CSL Limited Live and Attenuated Vaccine Product Portfolios and Specifications
Table 99. CSL Limited Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. CSL Limited Main Business
Table 101. CSL Limited Latest Developments
Table 102. Emergent BioSolutions, Inc. Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolios and Specifications
Table 104. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Emergent BioSolutions, Inc. Main Business
Table 106. Emergent BioSolutions, Inc. Latest Developments
Table 107. MedImmune, LLC Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. MedImmune, LLC Live and Attenuated Vaccine Product Portfolios and Specifications
Table 109. MedImmune, LLC Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. MedImmune, LLC Main Business
Table 111. MedImmune, LLC Latest Developments
Table 112. Sanofi Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Sanofi Live and Attenuated Vaccine Product Portfolios and Specifications
Table 114. Sanofi Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Sanofi Main Business
Table 116. Sanofi Latest Developments
Table 117. Serum Institute Basic Information, Live and Attenuated Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 118. Serum Institute Live and Attenuated Vaccine Product Portfolios and Specifications
Table 119. Serum Institute Live and Attenuated Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Serum Institute Main Business
Table 121. Serum Institute Latest Developments
LIST OF FIGURES
Figure 1. Picture of Live and Attenuated Vaccine
Figure 2. Live and Attenuated Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Live and Attenuated Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Live and Attenuated Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Live and Attenuated Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Live and Attenuated Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Live and Attenuated Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Pediatric Vaccine
Figure 12. Product Picture of Adult Vaccines
Figure 13. Global Live and Attenuated Vaccine Sales Market Share by Type in 2026
Figure 14. Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Live and Attenuated Vaccine Consumed in Hospitals
Figure 16. Global Live and Attenuated Vaccine Market: Hospitals (2021-2026) & (K Units)
Figure 17. Live and Attenuated Vaccine Consumed in Clinics
Figure 18. Global Live and Attenuated Vaccine Market: Clinics (2021-2026) & (K Units)
Figure 19. Live and Attenuated Vaccine Consumed in Diagnostic Centers
Figure 20. Global Live and Attenuated Vaccine Market: Diagnostic Centers (2021-2026) & (K Units)
Figure 21. Live and Attenuated Vaccine Consumed in Research Institute
Figure 22. Global Live and Attenuated Vaccine Market: Research Institute (2021-2026) & (K Units)
Figure 23. Live and Attenuated Vaccine Consumed in Others
Figure 24. Global Live and Attenuated Vaccine Market: Others (2021-2026) & (K Units)
Figure 25. Global Live and Attenuated Vaccine Sale Market Share by Application (2025)
Figure 26. Global Live and Attenuated Vaccine Revenue Market Share by Application in 2026
Figure 27. Live and Attenuated Vaccine Sales by Company in 2026 (K Units)
Figure 28. Global Live and Attenuated Vaccine Sales Market Share by Company in 2026
Figure 29. Live and Attenuated Vaccine Revenue by Company in 2026 ($ millions)
Figure 30. Global Live and Attenuated Vaccine Revenue Market Share by Company in 2026
Figure 31. Global Live and Attenuated Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Live and Attenuated Vaccine Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Live and Attenuated Vaccine Sales 2021-2026 (K Units)
Figure 34. Americas Live and Attenuated Vaccine Revenue 2021-2026 ($ millions)
Figure 35. APAC Live and Attenuated Vaccine Sales 2021-2026 (K Units)
Figure 36. APAC Live and Attenuated Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Europe Live and Attenuated Vaccine Sales 2021-2026 (K Units)
Figure 38. Europe Live and Attenuated Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Live and Attenuated Vaccine Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Live and Attenuated Vaccine Revenue 2021-2026 ($ millions)
Figure 41. Americas Live and Attenuated Vaccine Sales Market Share by Country in 2026
Figure 42. Americas Live and Attenuated Vaccine Revenue Market Share by Country (2021-2026)
Figure 43. Americas Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Figure 44. Americas Live and Attenuated Vaccine Sales Market Share by Application (2021-2026)
Figure 45. United States Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Live and Attenuated Vaccine Sales Market Share by Region in 2026
Figure 50. APAC Live and Attenuated Vaccine Revenue Market Share by Region (2021-2026)
Figure 51. APAC Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Figure 52. APAC Live and Attenuated Vaccine Sales Market Share by Application (2021-2026)
Figure 53. China Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. India Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Live and Attenuated Vaccine Sales Market Share by Country in 2026
Figure 61. Europe Live and Attenuated Vaccine Revenue Market Share by Country (2021-2026)
Figure 62. Europe Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Figure 63. Europe Live and Attenuated Vaccine Sales Market Share by Application (2021-2026)
Figure 64. Germany Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. France Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Live and Attenuated Vaccine Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Live and Attenuated Vaccine Sales Market Share by Application (2021-2026)
Figure 72. Egypt Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Live and Attenuated Vaccine in 2026
Figure 78. Manufacturing Process Analysis of Live and Attenuated Vaccine
Figure 79. Industry Chain Structure of Live and Attenuated Vaccine
Figure 80. Channels of Distribution
Figure 81. Global Live and Attenuated Vaccine Sales Market Forecast by Region (2027-2032)
Figure 82. Global Live and Attenuated Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Live and Attenuated Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Live and Attenuated Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Live and Attenuated Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Live and Attenuated Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Live and Attenuated Vaccine
Figure 2. Live and Attenuated Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Live and Attenuated Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Live and Attenuated Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Live and Attenuated Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Live and Attenuated Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Live and Attenuated Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Pediatric Vaccine
Figure 12. Product Picture of Adult Vaccines
Figure 13. Global Live and Attenuated Vaccine Sales Market Share by Type in 2026
Figure 14. Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Live and Attenuated Vaccine Consumed in Hospitals
Figure 16. Global Live and Attenuated Vaccine Market: Hospitals (2021-2026) & (K Units)
Figure 17. Live and Attenuated Vaccine Consumed in Clinics
Figure 18. Global Live and Attenuated Vaccine Market: Clinics (2021-2026) & (K Units)
Figure 19. Live and Attenuated Vaccine Consumed in Diagnostic Centers
Figure 20. Global Live and Attenuated Vaccine Market: Diagnostic Centers (2021-2026) & (K Units)
Figure 21. Live and Attenuated Vaccine Consumed in Research Institute
Figure 22. Global Live and Attenuated Vaccine Market: Research Institute (2021-2026) & (K Units)
Figure 23. Live and Attenuated Vaccine Consumed in Others
Figure 24. Global Live and Attenuated Vaccine Market: Others (2021-2026) & (K Units)
Figure 25. Global Live and Attenuated Vaccine Sale Market Share by Application (2025)
Figure 26. Global Live and Attenuated Vaccine Revenue Market Share by Application in 2026
Figure 27. Live and Attenuated Vaccine Sales by Company in 2026 (K Units)
Figure 28. Global Live and Attenuated Vaccine Sales Market Share by Company in 2026
Figure 29. Live and Attenuated Vaccine Revenue by Company in 2026 ($ millions)
Figure 30. Global Live and Attenuated Vaccine Revenue Market Share by Company in 2026
Figure 31. Global Live and Attenuated Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Live and Attenuated Vaccine Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Live and Attenuated Vaccine Sales 2021-2026 (K Units)
Figure 34. Americas Live and Attenuated Vaccine Revenue 2021-2026 ($ millions)
Figure 35. APAC Live and Attenuated Vaccine Sales 2021-2026 (K Units)
Figure 36. APAC Live and Attenuated Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Europe Live and Attenuated Vaccine Sales 2021-2026 (K Units)
Figure 38. Europe Live and Attenuated Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Live and Attenuated Vaccine Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Live and Attenuated Vaccine Revenue 2021-2026 ($ millions)
Figure 41. Americas Live and Attenuated Vaccine Sales Market Share by Country in 2026
Figure 42. Americas Live and Attenuated Vaccine Revenue Market Share by Country (2021-2026)
Figure 43. Americas Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Figure 44. Americas Live and Attenuated Vaccine Sales Market Share by Application (2021-2026)
Figure 45. United States Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Live and Attenuated Vaccine Sales Market Share by Region in 2026
Figure 50. APAC Live and Attenuated Vaccine Revenue Market Share by Region (2021-2026)
Figure 51. APAC Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Figure 52. APAC Live and Attenuated Vaccine Sales Market Share by Application (2021-2026)
Figure 53. China Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. India Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Live and Attenuated Vaccine Sales Market Share by Country in 2026
Figure 61. Europe Live and Attenuated Vaccine Revenue Market Share by Country (2021-2026)
Figure 62. Europe Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Figure 63. Europe Live and Attenuated Vaccine Sales Market Share by Application (2021-2026)
Figure 64. Germany Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. France Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Live and Attenuated Vaccine Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Live and Attenuated Vaccine Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Live and Attenuated Vaccine Sales Market Share by Application (2021-2026)
Figure 72. Egypt Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Live and Attenuated Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Live and Attenuated Vaccine in 2026
Figure 78. Manufacturing Process Analysis of Live and Attenuated Vaccine
Figure 79. Industry Chain Structure of Live and Attenuated Vaccine
Figure 80. Channels of Distribution
Figure 81. Global Live and Attenuated Vaccine Sales Market Forecast by Region (2027-2032)
Figure 82. Global Live and Attenuated Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Live and Attenuated Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Live and Attenuated Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Live and Attenuated Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Live and Attenuated Vaccine Revenue Market Share Forecast by Application (2027-2032)
